The effect of tumor sideness and mutational status on first line treatment response and survival in the patients with metastatic colorectal cancer

Basit Öğe Kaydı
dc.authorid0000-0002-7931-2941en_US
dc.contributor.authorEser, Kadir
dc.contributor.authorSezer, Emel Yaman
dc.contributor.authorÖztürk, Banu
dc.contributor.authorOnder, Arif Hakan
dc.contributor.authorErçolak, Vehbi
dc.contributor.authorOruç, Zeynep
dc.date.accessioned2021-07-27T13:31:39Z
dc.date.available2021-07-27T13:31:39Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.descriptionWOS:000591659400002
dc.description.abstractRAS and BRAF mutation and primary tumour sideness are prognostic and predictive factors in metastatic colorectal cancer (mCRC). We aimed to investigate RAS-BRAF mutation rates and responses to biologic agents the effects of tumour sideness on survival. This was a retrospective study conducted at three Turkish institutes. 303 patients with mCRC who were examined for tumour RAS and 172 examined for tumour BRAF mutations between 2006-2018. A total of 303 (M/F= 186/117) patients were included to study. Median age was 63 (range: 23-86) years. Median follow-up was 22.8 (range: 19.1-26.4) months. In the RAS wild type population; ad-dition to anti-EGFR agents to standard chemotherapy (CT) had better outcomes than Bevacizumab+CT. Median PFS was improved with anti-EGFR agents (Respectively PFS; 14.5 months, 8.7 months) (log rank p= 0.007 HR= 0.59). Median OS was similar between CT+anti-EGFR and CT+Bevacizumab arms (Respectively OS; 29.3 months, 21.7 months) (log rank p= 0.418; HR= 0.75). RAS mutation rates were similar between right colon cancer (RCC) and left colon cancer (LCC), BRAF mutation rates were significantly increased in RCC (22.2 vs 2.7%, p< 0.0001). RCC (24.1%) had worse prognosis than LCC (75.9%). However, this difference was not significant (PFS: 10.4 vs 10.0 months (log rank p= 0.136), OS: 21.5 vs 23.1 months (log rank p= 0.436). We concluded that in the patients with RAS wild type tumours, CT and anti-EGFR combination was reasonable approach for first line treatment. BRAF mutation, irrespective of CT regimen, was associated with poor survival and more common in RCC patients.en_US
dc.identifier.citationEser, K., Sezer, E. Y., Öztürk, B., Onder, A. H., Erçolak, V. ve Oruç, Z. (2020). The effect of tumor sideness and mutational status on first line treatment response and survival in the patients with metastatic colorectal cancer. Uluslararasi Hematoloji-Onkoloji Dergisi, 30(4), 1997-206.en_US
dc.identifier.doi10.4999/uhod.204659
dc.identifier.endpage206en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85098002835
dc.identifier.scopusqualityQ4
dc.identifier.startpage197en_US
dc.identifier.trdizinid419831
dc.identifier.urihttp://www.uhod.org/pdf/PDF_854.pdf
dc.identifier.urihttps://hdl.handle.net/11468/7244
dc.identifier.volume30en_US
dc.identifier.wosWOS:000591659400002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorOruç, Zeynep
dc.language.isoenen_US
dc.publisherAkademi Doktorlar Yayınevien_US
dc.relation.ispartofUluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic colorectal canceren_US
dc.subjectPrognosisen_US
dc.subjectRAS and BRAFen_US
dc.subjectSidednessen_US
dc.titleThe effect of tumor sideness and mutational status on first line treatment response and survival in the patients with metastatic colorectal canceren_US
dc.titleThe effect of tumor sideness and mutational status on first line treatment response and survival in the patients with metastatic colorectal cancer
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
The Effect of Tumor Sideness and Mutational.pdf
Boyut:
400.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu